Senseonics Announces Appointment of Francine R. Kaufman, M.D. as Chief Medical Officer
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced the appointment of Francine R. Kaufman, M.D.
as Chief Medical Officer, effective immediately.
“We are pleased to have Fran join the executive leadership team at
Senseonics. As Chief Medical Officer, she will be instrumental in
helping drive forward our innovation platform and the clinical value
proposition of the Eversense system,” said Tim Goodnow, President and
CEO of Senseonics. “Fran is one of the world’s leading endocrinologists
and her deep understanding of the global medical, research, and clinical
diabetes community coupled with her track record of applying novel
technologies to advance diabetes care for patients make her ideally
suited for the role. We are confident that with her leadership, we will
further transform and elevate the Eversense platform and bolster our US
commercialization efforts at this critical point.”
Dr. Kaufman’s career spans almost 40 years in diabetes care. She is a
dedicated pediatric endocrinologist and has served as director of the
Comprehensive Childhood Diabetes Center, and head of the Center for
Endocrinology, Diabetes and Metabolism at Children’s Hospital Los
Angeles. Dr. Kaufman is also a Distinguished Professor Emerita of
Pediatrics and Communications at the Keck School of Medicine and the
Annenberg School of Communications of the University of Southern
California. She was formerly the president of the American Diabetes
Association, chair of the National Diabetes Education Program and
elected to the National Academy of Medicine. She is the author of over
250 scientific manuscripts and numerous books, including Diabesity:
The Obesity-Diabetes Epidemic That Threatens America and the ADA’s
Insulin Pumps and Continuous Glucose Monitoring: A User’s Guide to
Effective Diabetes Management. Dr. Kaufman is an active
philanthropist working with numerous organizations and charities around
the world aimed at improving the lives of people with diabetes. She was
also an advisor to the Governor on the California Initiative on Health,
Fitness and Obesity. Most recently Dr. Kaufman served as Chief Medical
Officer and Vice President of Global Clinical, Regulatory and Medical
Affairs at Medtronic Diabetes. She received a Bachelor of Arts degree
from Northwestern University and was the Valedictorian of her class at
Chicago Medical School.
“I am very excited to join the Senseonics team, especially at this point
where I feel I have an opportunity to help lay the foundation for the
first long-term implantable continuous glucose monitoring system,” said
Dr. Kaufman. “I have spent my career exploring the treatment and
management of diabetes to improve outcomes for patients. I believe in
the clinical value the Eversense system provides and am eager to help
patients and providers realize its benefits.”
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformational glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. Senseonics' CGM systems, Eversense®
and Eversense® XL, include a small sensor inserted completely
under the skin that communicates with a smart transmitter worn over the
sensor. The glucose data is automatically sent every 5 minutes to a
mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005258/en/
Senseonics Investor Relations Contact:
Lynn Lewis or Philip
Taylor
Investor Relations
415-937-5406
[email protected]
Media Contact:
SignalWest Public Relations
Jeff
Christensen, 831-566-0275
[email protected]
Source: Senseonics Holdings, Inc.